Comparable stake leader
JANUS HENDERSON GROUP PLC
SEC ownership of Biohaven Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001935979.
Disclosed value leader
JANUS HENDERSON GROUP PLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- BHVN on NYSE
- Parsed ownership sources
- 13D/G and 13F
- Largest SEC-reported holder
- JANUS HENDERSON GROUP PLC
- Latest 13D/G holder
- JANUS HENDERSON GROUP PLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001935979
- Issuer location
- New Haven, CT
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Biohaven Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
JANUS HENDERSON GROUP PLC
Disclosed value leader
JANUS HENDERSON GROUP PLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 12%
13D/G row: JANUS HENDERSON GROUP PLC
Showing 1-8 of 50 holder rows.
Quick read
JANUS HENDERSON GROUP PLC leads the comparable SEC ownership view at 12%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens JANUS HENDERSON GROUP PLC's linked filing trail.
Comparable ownership
Top 5
JANUS HENDERSON GROUP PLC
12%
SUVRETTA CAPITAL MANAGEMENT, LLC
7.8%
VANGUARD GROUP INC
2.7%
BlackRock, Inc.
7.5%
STIFEL FINANCIAL CORP
6.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13D/G
13F
Company
|
12%
|
$177,450,273
17,534,612 shares
|
+$7,399,268 | 31 Mar 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13D/G
13F
Company
|
7.8%
|
$116,139,519
10,286,937 shares
|
$0 | 31 Dec 2025 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
2.7%
|
$43,156,602
2,875,190 shares
|
$0 | 30 Sep 2025 |
| BlackRock, Inc. |
13F
Company
|
7.5%
|
$94,941,564
11,222,407 shares
|
— | 31 Mar 2026 |
| STIFEL FINANCIAL CORP |
13F
Company
|
6.6%
|
$84,099,886
9,940,885 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
4.4%
|
$55,995,073
6,618,803 shares
|
— | 31 Mar 2026 |
| INFINITUM ASSET MANAGEMENT, LLC |
13F
Company
|
4.2%
|
$52,875,000
6,250,000 shares
|
— | 31 Mar 2026 |
| TCG Crossover Management, LLC |
13F
Company
|
3.1%
|
$39,180,942
4,631,317 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$33,144,763.
Buys
$33,144,763
Insiders: 4
Sells
$0
Insiders: 0
Net
+$33,144,763
Shares: +4,416,999
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 4,416,999
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 4,416,999 | 0 | $33,144,763 | $0 | +$33,144,763 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Biohaven Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
John W. Childs
Net 12M change
+$33,144,763
Latest report
28 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| John W. Childs | Director | $71,551,991 | +$24,999,998 | +54% | Mixed | 28 Apr 2026 |
| Vlad Coric | Chief Executive Officer, Director | $41,005,808 | +$4,999,995 | +14% | Mixed | 27 Feb 2026 |
| Gregory H. Bailey | Director | $15,150,532 | +$3,000,000 | +25% | Filing P/S | 28 Apr 2026 |
| Matthew Buten | Chief Financial Officer | $1,942,824 | Mixed | 27 Feb 2026 | ||
| Kimberly Gentile | SVP, Clinical Operations | $988,601 | Mixed | 27 Feb 2026 | ||
| George C. Clark | VP, Chief Accounting Officer | $890,891 | +$144,770 | +19% | Mixed | 27 Feb 2026 |
| Bruce Car | Chief Scientific Officer | $415,309 | Mixed | 27 Feb 2026 | ||
| Kishan Mehta | Director | $260,613 | Mixed | 28 Apr 2026 | ||
| Biohaven Pharmaceutical Holding Co Ltd. | 10%+ Owner | Mixed | 03 Oct 2022 | |||
| Irina Antonijevic | Director | Mixed | 28 Apr 2026 | |||
| Robert J. Hugin | Director | Mixed | 28 Apr 2026 | |||
| Julia P. Gregory | Director | Mixed | 28 Apr 2026 | |||
| Michael Thomas Heffernan | Director | Mixed | 28 Apr 2026 |
Recent insider transactions for Biohaven Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kishan Mehta | BHVN | Stock Options (Right to buy) | Award | 68,693 | 68,693 | 28 Apr 2026 | Direct | |||
| Gregory Bailey | BHVN | Stock Options (Right to buy) | Award | 68,693 | 68,693 | 28 Apr 2026 | Direct | |||
| Michael Thomas Heffernan | BHVN | Stock Options (Right to buy) | Award | 68,693 | 68,693 | 28 Apr 2026 | Direct | |||
| Irina Antonijevic | BHVN | Stock Options (Right to buy) | Award | 68,693 | 68,693 | 28 Apr 2026 | Direct | |||
| John W. Childs | BHVN | Stock Options (Right to buy) | Award | 68,693 | 68,693 | 28 Apr 2026 | Direct | |||
| Robert J. Hugin | BHVN | Stock Options (Right to buy) | Award | 68,693 | 68,693 | 28 Apr 2026 | Direct | |||
| Julia P. Gregory | BHVN | Stock Options (Right to buy) | Award | 68,693 | 68,693 | 28 Apr 2026 | Direct | |||
| Kishan Mehta | BHVN | Common Shares | Gift | 17,342 | 17,342 | 17 Mar 2026 | By Kishen Mehta 21 Family Irrevocable Trust | |||
| Kishan Mehta | BHVN | Common Shares | Gift | -76.5% | -17,342 | 5,320 | 17 Mar 2026 | Direct | ||
| Matthew Buten | BHVN | Stock Options (Right to buy) | Award | 175,000 | 175,000 | 27 Feb 2026 | Direct | |||
| Kimberly Gentile | BHVN | Stock Options (Right to buy) | Award | 175,000 | 175,000 | 27 Feb 2026 | Direct | |||
| George C. Clark | BHVN | Stock Options (Right to buy) | Award | 50,000 | 50,000 | 27 Feb 2026 | Direct | |||
| Bruce Car | BHVN | Stock Options (Right to buy) | Award | 175,000 | 175,000 | 27 Feb 2026 | Direct | |||
| Vlad Coric | BHVN | Stock Options (Right to buy) | Award | 550,000 | 550,000 | 27 Feb 2026 | Direct | |||
| Kimberly Gentile | BHVN | Common Shares | Tax liability | -1.93% | -1,956 | 99,557 | 05 Jan 2026 | Direct | ||
| Kimberly Gentile | BHVN | Common Shares | Options Exercise | 3.84% | 3,750 | 101,513 | 05 Jan 2026 | Direct | ||
| Kimberly Gentile | BHVN | Restricted Share Unit Award | Options Exercise | -33.3% | -3,750 | 7,500 | 05 Jan 2026 | Direct | ||
| Matthew Buten | BHVN | Common Shares | Tax liability | -1.31% | -2,594 | 195,652 | 05 Jan 2026 | Direct | ||
| Matthew Buten | BHVN | Common Shares | Options Exercise | 2.19% | 4,250 | 198,246 | 05 Jan 2026 | Direct | ||
| Matthew Buten | BHVN | Restricted Share Unit Award | Options Exercise | -33.3% | -4,250 | 8,500 | 05 Jan 2026 | Direct | ||
| Vlad Coric | BHVN | Common Shares | Tax liability | -0.41% | -7,430 | 1,803,968 | 05 Jan 2026 | Direct | ||
| Vlad Coric | BHVN | Common Shares | Options Exercise | 0.79% | 14,250 | 1,811,398 | 05 Jan 2026 | Direct | ||
| Vlad Coric | BHVN | Restricted Share Unit Award | Options Exercise | -33.3% | -14,250 | 28,500 | 05 Jan 2026 | Direct | ||
| Bruce Car | BHVN | Common Shares | Tax liability | -23.6% | -2,381 | 7,715 | 05 Jan 2026 | Direct | ||
| Bruce Car | BHVN | Common Shares | Options Exercise | 88.8% | 4,750 | 10,096 | 05 Jan 2026 | Direct | ||
| Bruce Car | BHVN | Restricted Share Unit Award | Options Exercise | -33.3% | -4,750 | 9,500 | 05 Jan 2026 | Direct | ||
| George C. Clark | BHVN | Common Shares | Tax liability | -1.64% | -1,117 | 66,978 | 05 Jan 2026 | Direct | ||
| George C. Clark | BHVN | Common Shares | Options Exercise | 3.81% | 2,500 | 68,095 | 05 Jan 2026 | Direct | ||
| George C. Clark | BHVN | Restricted Share Unit Award | Options Exercise | -33.3% | -2,500 | 5,000 | 05 Jan 2026 | Direct | ||
| George C. Clark | BHVN | Common Shares | Purchase | 566.7% | $144,770 | $8.52 | 17,000 | 20,000 | 17 Nov 2025 | By IRA |
| Gregory Bailey | BHVN | Common Shares | Purchase | 24.7% | $3,000,000 | $7.50 | 400,000 | 2,020,071 | 13 Nov 2025 | Direct |
| John W. Childs | BHVN | Common Shares | Purchase | 143.6% | $24,999,998 | $7.50 | 3,333,333 | 5,653,904 | 13 Nov 2025 | By John W Childs 2013 Revocable Trust |
| Vlad Coric | BHVN | Common Shares | Purchase | 81.9% | $2,499,998 | $7.50 | 333,333 | 740,546 | 13 Nov 2025 | By: The Vladimir Coric Marital Trust |
| Vlad Coric | BHVN | Common Shares | Purchase | 38.7% | $2,499,998 | $7.50 | 333,333 | 1,195,275 | 13 Nov 2025 | By: The Vlad Coric Family Trust |
* marks a reported price that did not pass the local price check.